JP2024542844A5 - - Google Patents
Info
- Publication number
- JP2024542844A5 JP2024542844A5 JP2024534268A JP2024534268A JP2024542844A5 JP 2024542844 A5 JP2024542844 A5 JP 2024542844A5 JP 2024534268 A JP2024534268 A JP 2024534268A JP 2024534268 A JP2024534268 A JP 2024534268A JP 2024542844 A5 JP2024542844 A5 JP 2024542844A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- dose
- alz
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163287552P | 2021-12-09 | 2021-12-09 | |
| US63/287,552 | 2021-12-09 | ||
| PCT/US2022/052331 WO2023107658A1 (en) | 2021-12-09 | 2022-12-09 | Alz-801 for use in treating alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024542844A JP2024542844A (ja) | 2024-11-15 |
| JP2024542844A5 true JP2024542844A5 (enExample) | 2025-12-11 |
Family
ID=85157530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024534268A Pending JP2024542844A (ja) | 2021-12-09 | 2022-12-09 | アルツハイマー病の処置に使用されるａｌｚ－８０１ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041248A1 (enExample) |
| EP (1) | EP4444286A1 (enExample) |
| JP (1) | JP2024542844A (enExample) |
| KR (1) | KR20240116529A (enExample) |
| CN (1) | CN118678950A (enExample) |
| AU (1) | AU2022405026A1 (enExample) |
| CA (1) | CA3240392A1 (enExample) |
| IL (1) | IL313404A (enExample) |
| MX (1) | MX2024007070A (enExample) |
| WO (1) | WO2023107658A1 (enExample) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3347002T (pt) * | 2015-09-10 | 2023-07-27 | Alzheon Inc | Tratamento de doença de alzheimer numa população particular de pacientes |
| DK3829563T3 (en) * | 2018-08-01 | 2025-02-24 | Alzheon Inc | 3-sulfopropanoic acid for treating neurodegenerative disorders |
-
2022
- 2022-12-09 IL IL313404A patent/IL313404A/en unknown
- 2022-12-09 MX MX2024007070A patent/MX2024007070A/es unknown
- 2022-12-09 CN CN202280091217.0A patent/CN118678950A/zh active Pending
- 2022-12-09 WO PCT/US2022/052331 patent/WO2023107658A1/en not_active Ceased
- 2022-12-09 EP EP22851094.7A patent/EP4444286A1/en active Pending
- 2022-12-09 US US18/717,139 patent/US20250041248A1/en active Pending
- 2022-12-09 CA CA3240392A patent/CA3240392A1/en active Pending
- 2022-12-09 JP JP2024534268A patent/JP2024542844A/ja active Pending
- 2022-12-09 AU AU2022405026A patent/AU2022405026A1/en active Pending
- 2022-12-09 KR KR1020247022383A patent/KR20240116529A/ko active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102795284B1 (ko) | 베타-히드록시부티레이트 및 부탄디올의 s-거울상이성질체 및 이의 사용 방법 | |
| US11957725B2 (en) | Methods for treating neurological disorders using nutrient compositions | |
| WO2012050895A1 (en) | Methods for treating neurological disorders using nutrient compositions | |
| JP2025512831A5 (enExample) | ||
| WO2009058005A2 (en) | Unit dosage for brain health | |
| CA2997376A1 (en) | Methods of treating neurodegenerative disorders in a particular patient population | |
| Guan et al. | FDCA attenuates neuroinflammation and brain injury after cerebral ischemic stroke | |
| CN101757624B (zh) | 一种预防和治疗老年痴呆症的组合物 | |
| CN117731653B (zh) | 人参环氧炔醇在制备治疗血管性痴呆药物中的应用及包含其的药物 | |
| EP3651759A1 (en) | Lithium salts of n-substituted glycine compounds and uses thereof | |
| JP7121859B2 (ja) | 安息香酸塩または安息香酸誘導体を含む、抗ｎ－メチル－ｄ－アスパラギン酸受容体脳炎を予防または治療するための医薬組成物 | |
| CN108078984B (zh) | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 | |
| US20230248726A1 (en) | Pharmaceutical composition and application thereof | |
| JP2023531750A5 (enExample) | ||
| TW201642847A (zh) | 用於靜脈內投與反丁烯二酸酯以治療神經疾病之方法及組合物 | |
| JP5807018B2 (ja) | 新規医薬組成物及びその使用 | |
| CN110141594A (zh) | 治疗阿尔茨海默症的药物 | |
| US20190254992A1 (en) | Combinations of beta-glycolipides and 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol, compositions and uses thereof in the treatment of disorders associated with protein misfolding and protein aggregations | |
| JP2024542844A (ja) | アルツハイマー病の処置に使用されるａｌｚ－８０１ | |
| AU2023358704A2 (en) | Methods of reducing physical dependence to neuropsychiatric treatments | |
| JP2025510556A (ja) | アルツハイマー型認知症に罹患している患者の治療において使用するためのスフィンゴシン－１－リン酸受容体（ｓ１ｐｒ）モジュレーター | |
| WO2023235937A1 (en) | Treatment of antidepressant resistant subjects | |
| WO2026037392A1 (zh) | 乳铁蛋白联合麦角硫因在制备预防和/或治疗阿尔茨海默症的药物中的用途 | |
| WO2021024855A1 (ja) | 線維筋痛症の治療薬又は予防薬 | |
| CN106659710A (zh) | 用于治疗多发性硬化的方法 |